申请人:American Cyanamid Company
公开号:US05852213A1
公开(公告)日:1998-12-22
This invention relates to matrix metalloproteinase (MMP) inhibiting compounds of the formula: ##STR1## where R.sup.1 is C.sub.1 -C.sub.12 alkyl, straight or branched and optionally substituted by halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, carboxyl, C.sub.1 -C.sub.6 alkoxycarbonyl, carboxamido, nitrile, mono- or di-(C.sub.1 -C.sub.6)alkylamino, thio, C.sub.1 -C.sub.6 alkylthio, aryl, --Oaryl or --OCH.sub.2 aryl where aryl is optionally substituted with C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, halogen, cyano, nitro, carboxamido, or hydroxy; and C.sub.1 -C.sub.6 alkanesulfonyloxy. R.sup.2 is .alpha.-OH or .beta.-OH and R.sup.6 is H or R.sup.2 and R.sup.6 together are carbonyl; the chemical intermediates; and processes for the preparation of these compounds and the intermediates thereto. Matrix metalloproteinases (MMP) are a family of zinc-containing calcium dependent proteinases, including stromelysins, collagenases, and gelatinases. These MMP enzymes are capable of degrading the proteinaceous components of connective tissue and appear to be involved in tissue remodeling, i.e., wound healing and connective tissue turnover. Unexpectedly, the mercaptoalcohols with the S-configuration at the hydroxyl-bearing carbon have been found to be at least 4 times more potent than the analogous (R)-alcohols both in vitro and in vivo in inhibiting the MMP enzyme.
这项发明涉及以下结构的基质金属蛋白酶(MMP)抑制化合物:其中R.sup.1是C.sub.1 -C.sub.12烷基,直链或支链,可选择地被卤素、羟基、C.sub.1 -C.sub.6烷氧基、氨基、羧基、C.sub.1 -C.sub.6烷氧羰基、羧胺基、腈基、单或双(C.sub.1 -C.sub.6)烷基氨基、硫基、C.sub.1 -C.sub.6烷硫基、芳基、--O芳基或--OCH.sub.2芳基取代,其中芳基可选择地被C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6烷氧基、羧基、卤素、氰基、硝基、羧胺基或羟基取代;以及C.sub.1 -C.sub.6烷磺酰氧基。R.sup.2是α-OH或β-OH,R.sup.6是H或R.sup.2,且R.sup.6与R.sup.2一起是羰基;这些化合物及其中间体的化学中间体;以及制备这些化合物和中间体的方法。基质金属蛋白酶(MMP)是一类含锌的依赖钙的蛋白酶家族,包括基质金属蛋白酶、胶原酶和明胶酶。这些MMP酶能够降解结缔组织的蛋白质成分,并似乎参与组织重塑,即伤口愈合和结缔组织更新。令人意外的是,在羟基位碳上具有S构型的巯基醇发现至少比类似的(R)-醇在体内外抑制MMP酶时更有效4倍。